Navigation Links
Prostate Cancer Patients Sought for Database as Part of Joint Effort

Men with prostate cancer and their spouses/significant others are being sought for a joint study being conducted by two Los Angeles-area medical centers as part of a// collaborative effort to better understand the genetics of the disease. Prostate cancer is the most common form of cancer in men.

Cedars-Sinai Medical Center’s Louis Warschaw Prostate Cancer Center at the Samuel Oschin Comprehensive Cancer Institute in Los Angeles is seeking participants for its Prostate Patient Profiles Project, in conjunction with Centinela Freeman Regional Medical Center, Memorial Campus in Inglewood. The goal of the Prostate Patient Profiles Project is to collect blood and tissue samples as well as medical information from men with prostate cancer and their spouses/significant others. It is hoped that the data collected will help doctors better understand the biology of prostate cancer as well as to study the factors that influence how different types of prostate cancers respond to treatment.

By teaming with Centinela Freeman’s Memorial Campus and its Urban Latino African American Cancer (ULAAC) Disparities Grant, researchers from Cedars-Sinai hope to reach a broad demographic range of patients, including underserved members of the community who may have difficulty gaining access to health care.

The ULAAC program, at Centinela Freeman, focuses on improving access to cancer clinical trials with patient navigators who help patients understand the treatment protocols, access treatment, and help patients deal with the physical and emotional aspects of a cancer diagnosis and treatment. It is hypothesized that minorities have worse cancer outcomes than whites because they reside too far from the traditional university setting where clinical trials are readily available. The ULAAC project not only brings clinical studies to the local community, but also helps patients access these trials through the navigator program, notes Michael Steinberg, M.D., prin cipal investigator for the Centinela Freeman ULAAC project.

“This data collection project is being undertaken because very little is known about what causes some individuals to develop cancer while others don’t,” said David B. Agus, M.D., research director for the Louis Warschaw Prostate Cancer Center and co-principal investigator on the project with Ronald Shazer, M.D.

“Once we better understand the genetic and proteomic patterns of men with prostate cancer, we hope to be able to develop more targeted, more individualized – and ultimately, more effective -- treatments for prostate and other cancers,” Dr. Agus said.

Participants must be at least 18 years of age and have prostate cancer and/or prostate disease. For the project, participants will be asked to give approximately four tablespoons of blood during routine blood work. Participants also will be asked to allow tissue removed in any surgeries that would otherwise be discarded to be stored in the repository for future research purposes. This tissue is taken during a scheduled surgery or from a stored sample from a prior surgery; no additional tissue will be removed solely for research purposes. Participants also provide their medical histories and fill out questionnaires. Spouses/significant others that agree to participate will give blood and fill out a questionnaire. If they have been diagnosed with cancer and have a stored tissue sample from a prior surgery, they can give permission to access these samples.

“Participating in this data collection study will not impact any treatment the prostate cancer patients are currently undergoing,” said Dr. Agus. “Rather, it will be used in laboratory settings for studies that will determine cellular growth characteristics of cancer cells, gene and protein expression, and help researchers develop more effective treatment approaches to fighting – and perhaps curing – cancer in the future.”

Prostate cancer is no t only the most common form of cancer in men, it is the second leading cause of cancer-related death among men living in the United States. Current treatments include surgery, radiation and hormone treatment as well as “watchful waiting.” Risk factors include age, ethnicity and family history.

“Prostate cancer is prevalent in our population and studies aimed at early detection will be extremely beneficial,” said Dr. Steinberg. “We hope that our patient’s involvement in these studies will help to provide better access to a continuum of cancer care.”

Source: Newswise)
'"/>




Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
3. New Prostate Cancer Vaccine Shows Promise
4. Hormone Therapy applicable for Prostate Cancer
5. Prostate cancer and Vitamins
6. Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time
7. Early Detection Of Prostate Cancer
8. Awareness increase Prostate cancer detection
9. Better Prostate Cancer Test
10. Stopping Prostate Cancer from Spreading
11. Drug might prevent Prostate Cancer Spread
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/27/2017)... ... ... The threat of nuclear warfare has long plagued this world. In July of ... of nuclear weapons. Years later, when her co-workers began dying, Dot started searching for ... Clayton exposes the critical decisions made by agencies involved in the nuclear testing during ...
(Date:2/27/2017)... Orange County, CA (PRWEB) , ... February 27, 2017 , ... ... for periodontitis. Periodontitis is a chronic inflammatory gum condition that occurs when the bacteria ... of deep cleaning, also referred to as a scaling and root planing or SRP, ...
(Date:2/27/2017)... ... 26, 2017 , ... Miro is the ultimate smart media center that offers ... movies, TV shows and much more apps for user exploration. Its innovative acoustic design ... of 1280 x 720 provides crisp images with remarkable clarity and color. The WiFi ...
(Date:2/27/2017)... ... 2017 , ... Texas based retail electric company Discount Power ... (Residential Customer Equivalent) count exceeds 150,000. , Discount Power was acquired ... 2,250 RCEs at the time of acquisition. In the three years since the ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... new informational post on robotic hair transplantation. San Francisco residents may be confused ... Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be used to ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... DUBLIN , Feb 28, 2017 ... "Digestive Enzyme Supplements Market Forecasts 2014-2025" report to their ... ... reach USD 1.6 billion by 2025. Growing consumer awareness regarding ... good health is expected to stimulate industry growth over the ...
(Date:2/27/2017)... 27, 2017 Halyard Health, Inc. (NYSE: ... and provided its 2017 outlook and related key planning assumptions. ... $410 million, a 2 percent increase compared to the prior ... 2016 was $10 million compared to net income of $15 ... net income was $24 million compared to adjusted net income ...
(Date:2/27/2017)... 27, 2017   Royal Philips (NYSE: ... leader in health technology, today announced 510(k) clearance ... to market its ElastQ Imaging capability, further expanding ... systems. ElastQ Imaging enables simultaneous imaging of tissue ... for the diagnosis of various liver conditions. With ...
Breaking Medicine Technology: